ARROTEX Pharmaceuticals has launched topical corticosteroid Xobet (clobetasol propionate 0.05%), which was recently listed on the Pharmaceutical Benefits Scheme (PBS).
The treatment is the most potent topical corticosteroid listed on the PBS, and provides a first-line treatment option for atopic dermatitis, psoriasis, lichen sclerosus/planus, alopecia areata, and discoid lupus erythematosus.
"We are proud to bring Xobet to every pharmacy across Australia, making this essential treatment for resistant or severe inflammatory corticosteroid-responsive dermatoses more accessible and affordable for patients," said Arrotex's General Manager of Innovation Monique Jonson.
"With Xobet now PBS-listed, Australians can access a high-quality, consistent product at a fraction of previous costs, ensuring equitable care at every community and hospital pharmacy nationwide," she said.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Jun 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Jun 25
